Le marché des particules de type virus (VLP) devrait atteindre 7 858,82 millions de dollars US d'ici 2028, contre 4 601,84 millions de dollars US en 2021 ; il devrait croître à un TCAC de 7,9 % de 2021 à 2028.
La commercialisation de particules virales -vaccins à base de virus humains et animaux, des activités vigoureuses de recherche et développement pour le développement de virus- Les vaccins viraux à base de particules similaires et les particules de type viral qui émergent comme une plate-forme d'immunothérapie fiable pour les maladies allergiques sont les principaux facteurs moteurs responsables de la croissance globale du marché. Cependant, les défis techniques liés à la conception, à la purification et au stockage des eVLP entravent la croissance globale du marché. De plus, les complexités associées à la fabrication de vaccins à particules pseudo-virales, associées aux coûts et aux délais excessifs des processus (tels que le traitement en aval des vaccins à base de particules pseudo-virales), limitent davantage la croissance du marché mondial. En outre, des thérapies à base de particules virales destinées aux maladies virales topiques et émergentes ainsi qu'au cancer sont toujours en cours de développement, ce qui offre des opportunités lucratives pour la croissance globale du marché.
Perspectives stratégiques
< p>L'Amérique du Nord devrait continuer à dominer le marché des particules de type viral au cours de la période 2021-2028. Les États-Unis détiennent la plus grande part du marché en Amérique du Nord et devraient poursuivre cette tendance au cours de la période de prévision. Ceci est principalement attribué à la sensibilité couramment observée des personnes aux infections virales, telles que la grippe virale causée par différentes variantes. De plus, les activités continues de R&D requises pour la fabrication de vaccins vivants atténués obligent les sociétés biopharmaceutiques à opter pour des particules de type viral, ce qui soutient davantage la croissance du marché.
Régions lucratives pour le marché des particules de type viral (VLP)
Aperçu du marché
Les vaccins à base de particules de type virus commercialisés stimulent la croissance globale du marché
Selon un rapport publié par Frontiers Media SA, le premier vaccin à base de particules virales a été conçu pour combattre un virus mortel, l'hépatite B, et les vaccins à base de particules virales ont produit des résultats de sécurité prometteurs par rapport aux vaccins traditionnels vaccins. Le premier vaccin à base de particules virales commercialisé était contre le VHB. En outre, les vaccins anti-VHB commerciaux, à savoir "Engerix" fabriqué par GlaxoSmithKline et "Recombivax HB" fabriqué par Merck & Co. ont été approuvés en 1980, et ils étaient tous des particules de type viral. Le prochain vaccin à base de particules virales disponible dans le commerce était "Gardasil", qui a été approuvé en 2006 pour prévenir les infections par le virus du papillome humain (VPH). De plus, les particules de type viral sont également utilisées en médecine vétérinaire. Le premier vaccin vétérinaire disponible dans le commerce à base de pseudo-particules virales s'est avéré efficace contre le circovirus porcin de type 2 (PCV2).
Le rôle des pseudo-particules virales dans le développement de produits d'immunothérapie contre les maladies allergiques stimule davantage la croissance globale du marché. les particules pseudo-virales sont utilisées dans le traitement de la rhinite allergique, de l'asthme et des réactions aux acariens. Les facteurs susmentionnés entraînent une croissance exponentielle du marché global des particules de type viral. les vaccins à particules pseudo-virales ont montré une réponse immunitaire rapide avec une légère réaction cutanée comme effets secondaires.
Informations basées sur le type de produit
En fonction du type de produit, le marché des particules de type viral est segmenté en hépatite, cancer/VPH et maladie de Gaucher. Le segment des hépatites représenterait une part de marché importante au cours de la période 2021-2028. Le rapport de Frontiers SA indique que le virus de l'hépatite C (VHC) infecte 2 % de la population mondiale et qu'il est l'une des principales causes de maladie du foie et de transplantation hépatique. Cette menace médicale peut être en partie combattue par l'introduction de nouvelles thérapies antivirales. Par exemple, un vaccin ayant une efficacité de 50 à 80 %, ciblant les toxicomanes à haut risque par voie intraveineuse, réduit considérablement l'incidence du VHC dans la population. Par conséquent, les particules de type viral représentent une plate-forme d'administration de vaccins sûre et hautement immunogène qui induit une réponse immunitaire adaptative. Plusieurs vaccins à base de pseudo-particules virales font actuellement l'objet d'essais cliniques ; cependant, les vaccins VLP homologués contre le VHB et le VPH sont utilisés depuis longtemps. Ainsi, les vaccins à base de particules de type viral ont prouvé leur efficacité en raison de caractéristiques immunologiques favorables et en font l'un des vaccins prometteurs contre le VHC.
Marché des particules de type viral (VLP), par type de produit - 2020 et 2028
Informations basées sur la source
Selon la source, le marché des particules de type viral (VLP) est segmenté en levure, cellule d'insecte, plante et autres. Le segment de la levure détient une part de marché considérable et devrait poursuivre la même tendance au cours de la période de prévision. les particules pseudo-virales sont produites par des systèmes d'expression hétérologues, impliquant des levures ou des baculovirus, ainsi que des plantes et des bactéries. La sécurité des vaccins à base de particules virales produites à l'aide de systèmes d'expression de levure contribue à la croissance du marché des particules virales à base de levure.
Application -Based Insights
Par application, le marché des particules pseudo-virales est segmenté en vaccins et thérapeutiques. Le segment des vaccins détiendrait une part considérable du marché en 2021, et il devrait également continuer à dominer le marché au cours de la période de prévision. La vaccination est considérée comme l'un des moyens les plus efficaces de contrôler les agents pathogènes et de prévenir les maladies, tant chez les humains que chez les animaux. Les vaccins à base de pseudo-particules virales représentent l'une des approches les plus intéressantes en raison de leurs propriétés immunogènes intrinsèques et de leur innocuité. Par exemple, les particules de type virus sont des antigènes multimères non infectieux ayant une structure particulaire, convenant à l'induction d'une réponse immunitaire humorale et cellulaire sûre et efficace. En dehors de cela, les vaccins à particules pseudo-virales ont prouvé leur efficacité dans le domaine vétérinaire. les particules de type viral ne sont composées que d'une ou plusieurs protéines structurelles sans présence de génomes de virus natifs et sans capacité d'auto-réplication dans les cellules. Cependant, des pseudo-particules virales contenant des antigènes monovalents ou multivalents peuvent être produites conformément à l'exigence d'une surveillance sérologique, l'utilité des vaccins à pseudo-particules virales s'avère prometteuse dans le domaine vétérinaire. Un exemple d'utilisation de vaccins à particules pseudo-virales dans le cadre de stratégies de vaccination Différenciant les animaux infectés des animaux vaccinés (DIVA) contre les maladies animales.
Les entreprises opérant sur le marché des particules pseudo-virales (VLP) adoptent la stratégie d'innovation produit pour répondre à l'évolution des demandes des clients à travers le monde, ce qui leur permet également de maintenir leur marque sur le marché mondial.
Marché des particules de type viral (VLP) - par type de produit
- Hépatite
- Cancer/VPH
- Maladie de Gaucher< /li>
Marché des particules de type viral (VLP) - par source
- Levure
- Cellule d'insecte
- Plante< /li>
- Autres
Marché des particules de type viral (VLP) par application
- Vaccins
- Thérapeutiques
Marché des particules de type viral (VLP) - par géographie
- Amérique du Nord
- États-Unis
- Canada
- Mexique
- Europe
- France
- Allemagne
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe
- Asie-Pacifique (APAC)
- Chine
- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'APAC
- Moyen-Orient et Afrique (MEA)
- Afrique du Sud
- Arabie saoudite
- EAU
- Reste du MEA
- Amérique du Sud et centrale (SCAM)
- Brésil
- Argentine
- Reste de la SCAM
Profils des entreprises
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global virus-like particles (VLP's) market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for virus-like particles (VLP’s). The US is estimated to hold the largest share in the virus-like particles (VLP’s) market during the forecast period. Presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for VLP’s accounting fastest growth of the region during the coming years.
Answer: - Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India Pvt. Ltd., BHARAT BIOTECH, LG Chem, and VBI Vaccines Inc. are among the leading companies operating in the global Virus-Like Particles (VLP's) market
The vaccine segment dominated the global virus-like particles (VLP's) market and accounted for the largest revenue of 4,558.08 Mn in 2021.
Based on product-type, hepatitis segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
American Society for Microbiology defines virus-like particles (VLP's) as non-infectious multiprotein structure that are engineered to self-assemble from viral structure proteins. VLP technology proves to be a very powerful tool involved in development of vaccines. Several VLP based vaccines exist in the global market involving hepatitis B virus and human papillomavirus.
Commercial VLP based vaccines against human and animal viruses, intensive research and development activities for the development of VLPs based vaccines effective against viral infections, and VLPs acting as the best immunotherapy platform for allergic diseases are the key driving factors responsible for the overall market growth.
The List of Companies - Virus-like Particles (VLP's) Market
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Nov 2021
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Nov 2021
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2021
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Nov 2021
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Nov 2021
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Nov 2021
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Nov 2021
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)